Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy

Hoffmann M, Sidarovich A, Arora P, Krueger N, Nehlmeier I, Kempf A, Graichen L, Winkler MS, Niemeyer D, Goffinet C, Drosten C, Schulz S, Jäck HM, Poehlmann S (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Mbio American Society for Microbiology: mBio / American Society for Microbiology

DOI: 10.1128/mbio.00364-22

Abstract

The interaction of the SARS-CoV-2 spike protein (S) with the cellular receptor ACE2 is considered essential for infection and constitutes the key target for antibodies induced upon infection and vaccination. Here, using a surrogate system for viral entry, we provide evidence that a naturally occurring mutation can liberate SARS-CoV-2 from ACE2-dependence and that ACE2-independent entry may protect the virus from neutralization by an antibody used for COVID-19 therapy.

Authors with CRIS profile

Sebastian Schulz Professur für Immunologie Hans-Martin Jäck Department of Molecular Immunology

Involved external institutions

Deutsches Primatenzentrum (DPZ), Leibniz-Institut für Primatenforschung DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Göttingen DE Germany (DE)

How to cite

APA:

Hoffmann, M., Sidarovich, A., Arora, P., Krueger, N., Nehlmeier, I., Kempf, A.,... Poehlmann, S. (2022). Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy. Mbio. https://doi.org/10.1128/mbio.00364-22

MLA:

Hoffmann, Markus, et al. "Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy." Mbio (2022).

BibTeX: Download